🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Taiwan / NCT07351240
Active, not recruiting Not applicable

The Acupuncture Treatment Effect in Patients With Schizophrenia

NCT07351240 · tracked via the Priya Life Science Taiwan tracker
Sponsor
Calo Psychiatric Center
Phase
Not applicable
Started
2025-12-16
Last updated
2026-01-22

Condition(s) studied

Mental Health

Investigational drug(s) / intervention(s)

Acupuncture

Acupuncture: Both the Neiguan and Shenmen groups will receive acupuncture treatment twice weekly, with each session lasting 30 minutes, for a total of four consecutive weeks. Assessments will be conducted prior to acupuncture intervention and after each acupuncture session.

Study summary

Among various psychiatric disorders, this study focuses specifically on patients with schizophrenia. The aim of this study is to evaluate the therapeutic effects of acupuncture on antipsychotic medication-related side effects and psychiatric symptoms in patients with schizophrenia. This is a single-blind randomized study. Participants will be randomly assigned to one of two groups: Neiguan and Shenmen. Both the Neiguan and Shenmen groups will receive acupuncture treatment twice weekly, with each session lasting 30 minutes, for a total of four consecutive weeks. Assessments will be conducted prior to acupuncture intervention and after each acupuncture session. All assessment data will be collected and analyzed using statistical methods including descriptive statistics, chi-square tests, and t-tests. Generalized Estimating Equations (GEE-I) and multiple linear regression analyses will be applied to examine differences in psychological health, quality of life, and happiness before and after acupuncture intervention. It is anticipated that acupuncture will reduce antipsychotic-related side effects, improve psychiatric symptoms in patients with schizophrenia, and subsequently enhance patients' quality of life and happiness.

Eligibility

Sex
ALL
Min age
20 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Diagnosis of schizophrenia according to DSM-5 criteria for at least six months * Personal and Social Performance Scale score ≥ 50 Exclusion Criteria: * Severe medical illnesses (e.g., cancer, chronic liver disease, renal failure) * History of stroke or other causes of hemiplegia * Severe dermatological disease or limb edema * High risk of violence or suicide * Alcohol or substance abuse or dependence * Severe cognitive impairment * Pregnancy or breastfeeding * Severe hepatic, renal, cardiac, pulmonary, or hematological disease * Major infectious diseases (e.g., HIV infection) * Refusal to provide informed consent

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Calo Psychiatric Center Pingtung City Taiwan

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07351240 on ClinicalTrials.gov ↗ ← All trials in Taiwan